文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-PSMA-617治疗复发或转移性涎腺癌的初步经验

First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer.
PubMed 文献 · EJNMMI Res · 2021-12-14

本研究回顾性评估177Lu-PSMA-617作为复发或转移性涎腺癌末线治疗的有效性。6例患者接受治疗,2例出现影像学缓解(疾病稳定或部分缓解),4例报告肿瘤相关症状即刻缓解。作者认为该姑息治疗可能快速缓解不适并可能诱导疾病稳定,安全性较好,可在常规治疗失败后考虑。

要点

  • 6例复发或转移性涎腺癌患者接受177Lu-PSMA-617姑息治疗。
  • 2例出现影像学缓解(疾病稳定或部分缓解),4例报告症状即刻缓解。
  • 作者认为可在常规治疗选择失败时考虑该治疗。

核心结论

  • 涎腺癌的姑息性177Lu-PSMA治疗可能快速缓解肿瘤相关不适,并可能诱导疾病稳定。
  • 该治疗安全、耐受性相对较好,可在常规治疗选择失败时考虑。

研究设计与样本

  • 本研究为回顾性评估,旨在评价177Lu-PSMA-617对复发或转移性涎腺癌作为末线治疗的有效性。
  • 选择无常规治疗选择且伴有严重肿瘤相关不适的患者,由肿瘤委员会重新评估。
  • 当68Ga-PSMA-PET/CT上肿瘤靶向摄取高于肝脏SUVmax时确认适合接受放射性核素治疗。
  • 方案计划每6-8周给予6.0-7.4 GBq 177Lu-PSMA-617,共四周期。
  • 共6例患者接受177Lu-PSMA治疗:4例腺样囊性癌、1例腺癌NOS、1例腺泡细胞癌。

主要发现

  • 2例患者观察到影像学缓解,表现为疾病稳定或部分缓解。
  • 4例患者报告肿瘤相关症状即刻缓解。
  • 最常见副作用为1-2级乏力、恶心、骨痛和口干。
  • 4例患者提前终止治疗:3例因疾病进展,1例因令人沮丧的(1级)副作用。

关键数值与推荐

  • 肿瘤靶向摄取大于肝脏SUVmax(68Ga-PSMA-PET/CT)时确认适合放射性核素治疗。
  • 方案计划每6-8周给予6.0-7.4 GBq 177Lu-PSMA-617,共四周期。
  • 临床反应通过问卷评估,影像学反应通过68Ga-PSMA-PET/CT评估。

临床怎么用

  • 作者认为,当常规治疗选择失败时,可考虑将姑息性177Lu-PSMA治疗用于涎腺癌。

局限性

  • 本研究为回顾性评估。
  • 样本量为6例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advanced salivary gland cancers become difficult to treat when they are technically irresectable and radiotherapy limits are exceeded. There is also an unmet need to improve palliative systemic therapy. Salivary glands depict the Prostate-Specific Membrane Antigen (PSMA) on 68Ga-PSMA-PET/CT, a transmembrane protein that is targeted for diagnosis and treatment of advanced prostate cancer. Some salivary gland carcinomas also express PSMA. METHODS: This study aimed to retrospectively evaluate the effectiveness of 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancers, as a last resort treatment. Patients with serious tumour-related discomfort for whom no regular option was available were selected and critically re-assessed by the tumour board. Radionuclide therapy eligibility was confirmed when tumour targeting was greater than liver SUVmax on 68Ga-PSMA-PET/CT. The protocol aimed at four cycles of 6.0-7.4 GBq 177Lu-PSMA-617 every 6-8 weeks. Clinical response was evaluated by questionnaires and radiological response by 68Ga-PSMA-PET/CT. RESULTS: Six patients were treated with 177Lu-PSMA: four adenoid cystic carcinomas, one adenocarcinoma NOS and one acinic cell carcinoma. In two patients, radiological response was observed, showing either stable disease or a partial response, and four patients reported immediate relief of tumour-related symptoms. Most reported side effects were grade 1-2 fatigue, nausea, bone pain and xerostomia. Four patients prematurely discontinued therapy: three due to disease progression and one due to demotivating (grade 1) side-effects. CONCLUSIONS: Palliative 177Lu-PSMA therapy for salivary gland cancer may lead to rapid relief of tumour-associated discomfort and may even induce disease stabilization. It is safe, relatively well tolerated and can be considered when regular treatment options fail.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Klein Nulent TJW, van Es RJJ, Willems SM, et al. First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer. EJNMMI Res. 2021. PMID: 34905121. doi:10.1186/s13550-021-00866-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。